The company reached a deal last fall to settle thousands of opioid lawsuits in return for $250 million in cash and $23 billion worth of drugs used to treat addiction.Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com Drugmakers have fallen into two categories this earnings season: those that maintained the revenue projections they set out early this year, and those that have cut those forecasts in light of the pandemic.